Polycystic kidney disease currently exhibits a growing pipeline with approximately 16 drug candidates, According to P&S Market Research
The study analyzed that the polycystic kidney disease (PKD) therapeutics pipeline comprises approximately 16 drug candidates in different stages of development. PKD affects kidney along with other organs, in which development of cyst interrupts the ability to filter the waste products from blood. The disease is mostly related to high blood pressure, blood in urine, pain in back, kidney stones and heart valve abnormalities. Enlargement of cyst may lead to kidney failure which can in turn impact other organs. People with PKD are at a risk of developing aneurysm in aorta or in blood vessels in base of the brain. The disease can be categorized into two types, as autosomal dominant polycystic kidney disease (AKPKD), and autosomal recessive polycystic kidney disease (ARPKD). AKPKD generally diagnosed in adulthood, while ARPKD diagnosed in earliest months of life.
Insights on pipeline segments
According to the research findings, most of the drug candidates of the PKD are being developed to be administered by the oral route.
Surge in the development of Pre-Clinical and Discovery Drug Candidates
Many pharmaceutical companies are involved in the development of therapeutic compounds by overcoming the challenges, that are effective in the treatment of PKD. They are focusing on developing the maximum drug candidates in the Pre-Clinical and Discovery stage of development. The pipeline consists of approximately eight drug candidates in the Pre-Clinical stage. GLG Pharma is in the process of developing two drug candidates in Pre-Clinical stage.
Access Report Summary with Detailed TOC on “Polycystic Kidney Disease (PKD) Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments” at: https://www.psmarketresearch.com/market-analysis/polycystic-kidney-disease-therapeutics-pipeline-analysis
Increased Funding by the Government Organizations Contributing Immensely in Pipeline Growth
Novatarg Pharmaceuticals, received $3.2 million funding by Small Business Innovation Research (SBIR), a part of governmental agencies of National Institutes of Health, to further conduct clinical study in PKD. Novatarg Pharmaceuticals, is in the process of research and development activities of NT 1044. Through the funding, NovaTarg Pharmaceuticals had further planned to progress drug candidates for PKD and type II diabetes mellitus. In addition, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is also supporting the pharmaceutical companies to conduct clinical study and research on PKD to improve patient health.
Some of the key players developing drugs for the treatment of PKD therapeutics include Otsuka Pharmaceutical Co., Ltd., Exelixis, Inc., and XORTX Pharma Corp.
Polycystic Kidney Disease Therapeutics Pipeline Analysis